JNJ-10198409, a relatively selective, orally active, and ATP competitive PDGF-RTK (platelet-derived growth factor receptor tyrosine kinase) inhibitor with IC50 of 2 nM, is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent, has good activity against PDGFRβ kinase and PDGFRα kinase with IC50 of 4.2 and 45 nM, respectively.